Literature DB >> 10826485

Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.

P Silvera1, P Racz, K Racz, N Bischofberger, C Crabbs, J Yalley-Ogunro, J Greenhouse, J B Jiang, M G Lewis.   

Abstract

In this study we compared the effect of postexposure treatment of the acyclic nucleoside analogs 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) and 9-(2-phosphonylmethoxypropyl)-adenine (PMPA) on the kinetics of viral load in the blood and lymph nodes of rhesus macaques chronically infected with SIVmac251 for 18 weeks. Two of the four macaques treated with PMPA (20 mg/kg per day) for 28 consecutive days had demonstrable reductions in viral loads of 1.5 and 3 logs. Three of four macaques given the same dosing regimen of PMEA had viral load reductions ranging from 1.25 to 2.8 logs. Furthermore, treatment with either drug caused a reduction in virus burden in the lymph nodes by 2 weeks posttreatment. However, in both PMEA- and PMPA-treated animals, viral loads rebounded to day of treatment levels by 2 weeks after termination of treatment. The extent to which viral load was suppressed was similar for both drugs. In contrast, viral loads in three of four mock-treated animals remained persistently high throughout the study. This study has demonstrated that postexposure treatment with these acyclic nucleoside analogs could modulate the kinetics of viral load reduction in some animals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10826485     DOI: 10.1089/088922200308783

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  6 in total

1.  Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production.

Authors:  Z Zídek; D Franková; A Holý
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Memory CD4(+) T cells are the earliest detectable human immunodeficiency virus type 1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1 transmission in an organ culture system.

Authors:  Phalguni Gupta; Kelly B Collins; Deena Ratner; Simon Watkins; Gregory J Naus; Daniel V Landers; Bruce K Patterson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Authors:  Karin J Metzner; James M Binley; Agegnehu Gettie; Preston Marx; Douglas F Nixon; Ruth I Connor
Journal:  Retrovirology       Date:  2006-12-21       Impact factor: 4.602

4.  Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model.

Authors:  Riti Sharan; Shashank R Ganatra; Allison N Bucsan; Journey Cole; Dhiraj K Singh; Xavier Alvarez; Maya Gough; Cynthia Alvarez; Alyssa Blakley; Justin Ferdin; Rajesh Thippeshappa; Bindu Singh; Ruby Escobedo; Vinay Shivanna; Edward J Dick; Shannan Hall-Ursone; Shabaana A Khader; Smriti Mehra; Jyothi Rengarajan; Deepak Kaushal
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 19.456

5.  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Authors:  Koen K A Van Rompay; Jeffrey A Johnson; Emily J Blackwood; Raman P Singh; Jonathan Lipscomb; Timothy B Matthews; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger; Walid Heneine; Thomas W North
Journal:  Retrovirology       Date:  2007-04-06       Impact factor: 4.602

6.  Antiretroviral therapy does not reduce tuberculosis reactivation in a tuberculosis-HIV coinfection model.

Authors:  Shashank R Ganatra; Allison N Bucşan; Xavier Alvarez; Shyamesh Kumar; Ayan Chatterjee; Melanie Quezada; Abigail Fish; Dhiraj K Singh; Bindu Singh; Riti Sharan; Tae-Hyung Lee; Uma Shanmugasundaram; Vijayakumar Velu; Shabaana A Khader; Smriti Mehra; Jyothi Rengarajan; Deepak Kaushal
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 19.456

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.